Bayer posts Phase 3 gadoquatrane brain/spine MRI results; ARI2 Eylea data remain on file

Two registry updates are on record for the week, one new and one carried over from a prior posting.

• Gadoquatrane, Bayer's lower-dose gadolinium contrast agent, was tested head-to-head against approved macrocyclic GBCAs in a Phase 3 crossover trial for people with known or suspected CNS pathology undergoing MRI. The trial enrolled 321 participants and used a randomized, crossover design with quadruple masking.¹ Primary completion was recorded as 2024-05-30, with results first posted on 2026-10-08.¹ Contrast enhancement was judged by blinded independent central reviewers comparing unenhanced and gadoquatrane-enhanced MRI sets, scored on a 4-point scale from not enhanced to clearly and brightly enhanced.¹
• The ARI2 study, sponsored by Centre Hospitalier Intercommunal Creteil with Bayer as a collaborator, tested aflibercept (Eylea) in wet AMD patients previously treated with ranibizumab (Lucentis). The Phase IIIb trial evaluated whether Eylea could induce regression of pigment epithelium detachment height in patients extensively treated with Lucentis.² Enrollment reached 84 participants in a single-group design.² Results were first posted on 2026-10-05, a date that remains unchanged from the prior report.